Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Augmented BFM Therapy for Infant ALL
NCT00022126Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Nov 2002
- Primary completion
- Jan 2005
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Replacement Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of dexamethasone, daunorubicin, vincristine, asparaginase escherichia coli, methotrexate in acute lymphoblastic leukemia (ALL), sponsored by Children's Oncology Group. Started Nov 2002; status: completed.
02
Drugs
dexamethasonedaunorubicinvincristineasparaginase escherichia colimethotrexate
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00022126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022126.